LL-37, human
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


LL-37, human
Description :
LL-37, human is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. LL-37, human could help protect the cornea from infection and modulates wound healing[1][2][3].UNSPSC :
12352209Target :
BacterialType :
PeptidesRelated Pathways :
Anti-infectionApplications :
COVID-19-immunoregulationField of Research :
InfectionAssay Protocol :
https://www.medchemexpress.com/ll-37-human.htmlPurity :
99.60Solubility :
H2O : 50 mg/mL (ultrasonic)Smiles :
O=C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N5[C@@H](CCC5)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)NMolecular Formula :
C205H340N60O53Molecular Weight :
4493.26References & Citations :
[1]Dürr UH, et al. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006 Sep;1758 (9) :1408-25.|[2]Huang LC, et al. Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. Invest Ophthalmol Vis Sci. 2006 Jun;47 (6) :2369-80.|[3]Hou M, et al. Antimicrobial peptide LL-37 and IDR-1 ameliorate MRSA pneumonia in vivo. Cell Physiol Biochem. 2013;32 (3) :614-23.Shipping Conditions :
Blue IceStorage Conditions :
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)Scientific Category :
PeptidesClinical Information :
No Development ReportedCitation 01 :
ACS Omega. 2025 Aug 12;10 (33) :36994-37003.|Commun Biol. 2022 Jun 8;5 (1) :559.|FASEB J. 2025 Oct 31;39 (20) :e71164.|Int Immunopharmacol. 2024 Mar 10:129:111636.CAS Number :
[154947-66-7]

